2026-2034年全球溶瘤病毒免疫療法市場規模、佔有率、趨勢和成長分析報告

溶瘤病毒免疫療法的市場規模預計將從 2025 年的 4.9079 億美元成長到 2034 年的 31.672 億美元，2026 年至 2034 年的複合年成長率為 23.02%。

由於對創新癌症治療方案的需求不斷成長，全球溶瘤病毒免疫療法市場正蓬勃發展。溶瘤病毒因其能夠選擇性感染並摧毀癌細胞，同時刺激免疫系統，而備受關注，被視為一種極具前景的治療方法。癌症發生率的上升和人們對標靶治療日益成長的興趣是推動市場成長的主要因素。此外，生物技術和免疫療法的進步也為新型溶瘤病毒治療方法的研發提供了支持。

關鍵成長要素包括癌症研究投入的增加以及以免疫療法為重點的臨床試驗數量的成長。向個人化醫療和聯合治療的轉變也促進了市場擴張。製藥公司與研究機構之間的合作正在加速創新和商業化進程。此外，監管機構對先進治療方法的支持以及快速核准機制也在推動市場發展。

隨著更多治療方法進入臨床試驗並獲得核准，溶瘤病毒免疫療法市場預計將迎來顯著成長。基因工程技術的進步將提升這些治療方法的療效和安全性。在新興市場，醫療基礎設施的改善和癌症防治意識的提高可能會帶來巨大的成長機會。此外，持續的研究也將繼續拓展溶瘤病毒療法的潛在應用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球溶瘤病毒免疫療法市場：依病毒類型分類

• 市場分析、洞察與預測
• 單純皰疹病毒（HSV）
• 腺病毒
• 牛痘病毒
• 新城疫病毒
• 呼腸孤病毒
• 其他病毒種類

第5章 全球溶瘤病毒免疫療法市場：依給藥途徑分類

• 市場分析、洞察與預測
• 腫瘤內部
• 靜脈注射
• 其他給藥途徑

第6章 全球溶瘤病毒免疫療法市場：依應用分類

• 市場分析、洞察與預測
• 黑色素瘤
• 乳癌
• 肺癌
• 卵巢癌
• 攝護腺癌
• 其他用途

第7章 全球溶瘤病毒免疫療法市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 癌症研究機構
• 門診手術中心
• 其他最終用戶

第8章 全球溶瘤病毒免疫療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • Creative Biolabs
  • Daiichi Sankyo Company Limited
  • Genelux Corporation
  • Oncorus Inc
  • Replimune Group Inc
  • SIGA Technologies Inc
  • Sorrento Therapeutics Inc
  • TILT Biotherapeutics Ltd
  • Viralytics Ltd

The Oncolytic Virus Immunotherapy Market size is expected to reach USD 3167.20 Million in 2034 from USD 490.79 Million (2025) growing at a CAGR of 23.02% during 2026-2034.

The global oncolytic virus immunotherapy market is gaining momentum due to the increasing demand for innovative cancer treatment solutions. Oncolytic viruses selectively infect and destroy cancer cells while stimulating the immune system, making them a promising therapeutic approach. The rising prevalence of cancer and the growing focus on targeted therapies are key factors driving market growth. Additionally, advancements in biotechnology and immunotherapy are supporting the development of novel oncolytic virus treatments.

Key growth drivers include increasing investments in cancer research and the growing number of clinical trials focused on immunotherapy. The shift toward personalized medicine and combination therapies is also contributing to market expansion. Collaborations between pharmaceutical companies and research institutions are accelerating innovation and commercialization. Furthermore, regulatory support and fast-track approvals for advanced therapies are boosting market development.

In the future, the oncolytic virus immunotherapy market is expected to witness substantial growth as more therapies progress through clinical trials and receive approval. Technological advancements in genetic engineering will enhance the efficacy and safety of these treatments. Emerging markets are likely to offer significant growth opportunities due to improving healthcare infrastructure and rising cancer awareness. Additionally, ongoing research will continue to expand the potential applications of oncolytic virus therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Virus Type

• Herpes Simplex Virus (HSV)
• Adenovirus
• Vaccinia Virus
• Newcastle Disease Virus
• Reovirus
• Other Virus Types

By Route of Administration

• Intratumoral
• Intravenous
• Other Routes of Administration

By Application

• Melanoma
• Breast Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Other Applications

By End-User

• Hospitals & Clinics
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Other End-Users

COMPANIES PROFILED

• Amgen Inc, Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc, Replimune Group Inc, SIGA Technologies Inc, Sorrento Therapeutics Inc, TILT Biotherapeutics Ltd, Viralytics Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY VIRUS TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Virus Type
• 4.2. Herpes Simplex Virus (HSV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Newcastle Disease Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Reovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Other Virus Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Intratumoral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Routes of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Virus Type
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Virus Type
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Virus Type
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Virus Type
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Virus Type
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen Inc
  • 10.2.2 Creative Biolabs
  • 10.2.3 Daiichi Sankyo Company Limited
  • 10.2.4 Genelux Corporation
  • 10.2.5 Oncorus Inc
  • 10.2.6 Replimune Group Inc
  • 10.2.7 SIGA Technologies Inc
  • 10.2.8 Sorrento Therapeutics Inc
  • 10.2.9 TILT Biotherapeutics Ltd
  • 10.2.10 Viralytics Ltd